Methyl salicylate/menthol topical - Futura Medical

Drug Profile

Methyl salicylate/menthol topical - Futura Medical

Alternative Names: SPR-300

Latest Information Update: 16 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Futura Medical
  • Class Anti-inflammatories; Cyclohexanols; Monoterpenes; Non-opioid analgesics; Salicylates
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 14 Jul 2015 Futura Medical completes a phase I trial with three topical NSAID products in Pain (volunteers) in United Kingdom
  • 30 Mar 2015 Methyl salicylate/menthol topical - Futura Medical is available for licensing as of 01 Jul 2013. http://www.futuramedical.com/
  • 18 Mar 2015 Phase-I clinical trials in Pain (In volunteers) in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top